Category: Edwards Lifesciences
Patients who've already had coronary artery bypass graft surgery showed a significant mortality benefit with Medtronic's CoreValve replacement heart valve than with open heart surgery, according to a clinical trial.
MassDevice.com asks medical device CEOs about the key issues of 2014 and what's ahead for the New Year.
As 2014 draws to a close, MassDevice.com asked several medical device company CEOs for their takes on 2014 and what they're looking for in 2015.
We wanted to get their views on the major trends seen in medtech this year, including the red-hot M&A and IPO scenes, the medical device tax, the regulatory environment in the U.S., and more.
Here's a look at some of the top legal news stories for medical device companies this week: CardioKinetix raises $50m, inks buyout deal with Edwards Lifesciences; Angel Medical raises $10m for ischemia devices; Zyga Technology raises $2m; Image Stream Medical looks at $8m
A clinical study delivers positive results for replacement heart valves made by rivals Edwards Lifesciences and Medtronic in treating bicuspid disease.
Michael Mussallem, CEO, Edwards Lifesciences says FDA regulators are looking to speed up approvals for medical devices
(Reuters) - U.S. health regulators appear open to speeding up approvals of medical devices that currently often reach European markets three to five years ahead of being cleared in the United States, the chief executive officer of Edwards Lifesciences (NYSE:EW) said.
CardioKinetix signs an exclusive option-to-buy agreement with Edwards Lifesciences in connection with a $50 million financing round.
Edwards Lifesciences affirms its outlook for 2014 and reveals its 2015 guidance, along with an increased investment in CardioKinetix and a new leader for its critical care business lured from Medtronic.